

# Maria Orietta Borghi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1901138/maria-orietta-borghi-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122  
papers

4,250  
citations

38  
h-index

61  
g-index

134  
ext. papers

5,004  
ext. citations

5.9  
avg, IF

5.13  
L-index

#	Paper	IF	Citations
122	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , <b>2021</b> , 60, 1114-1124	3.9	19
121	Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 937-950	5.6	3
120	Histone Deacetylase Inhibitors Ameliorate Morphological Defects and Hypoexcitability of iPSC-Neurons from Rubinstein-Taybi Patients. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
119	Antibodies and diagnostic tests in antiphospholipid syndrome <b>2021</b> , 565-574		1
118	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1073-1085	9.5	27
117	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. <i>Journal of Autoimmunity</i> , <b>2021</b> , 116, 102560	15.5	57
116	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2021</b> , 92, 221-223	5.5	2
115	α <sub>2</sub> glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2021</b> , 41, 2038-2053	7.3	3
114	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 726820	8.4	4
113	Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 715-726	8.1	28
112	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 265	5.7	5
111	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102509	13.6	8
110	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102525	13.6	13
109	Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome <b>2020</b> ,		8
108	Complement Activation and Thrombin Generation by MBL Bound to α <sub>2</sub> -Glycoprotein I. <i>Journal of Immunology</i> , <b>2020</b> , 205, 1385-1392	5.3	7
107	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 584241	8.4	86
106	Two Novel Technologies for the Detection of Anti-cardiolipin and Anti α <sub>2</sub> -Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays. <i>Immunological Investigations</i> , <b>2020</b> , 49, 58-68	2.9	2

105	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 773	8.4	14
104	Interleukin-17/Interleukin-21 and Interferon- $\gamma$ -producing T cells specific for $\beta$ 2-Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. <i>Haematologica</i> , <b>2019</b> , 104, 2519-2527	6.6	15
103	Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2019</b> , 57, 1764-1769	5.9	11
102	New insight into antiphospholipid syndrome: antibodies to $\beta$ 2-glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , <b>2019</b> , 104, 819-826	6.6	21
101	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. <i>Analytical Biochemistry</i> , <b>2019</b> , 566, 133-138	3.1	5
100	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e50	2.4	15
99	Beyond thrombosis: Anti- $\beta$ 2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , <b>2018</b> , 90, 76-83	15.5	41
98	Diagnostic laboratory tests for systemic autoimmune rheumatic diseases: unmet needs towards harmonization. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2018</b> , 56, 1743-1748	5.9	17
97	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1388	8.4	28
96	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 433-440	8.1	61
95	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. <i>Open Rheumatology Journal</i> , <b>2018</b> , 12, 248-260	0.2	3
94	Effects of human recombinant type I IFNs (IFN- $\alpha$ 2b and IFN- $\alpha$ 1a) on growth and migration of primary endometrial stromal cells from women with deeply infiltrating endometriosis: A preliminary study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2018</b> , 230, 192-198	2.4	3
93	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 1153-1168	13.6	43
92	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 187	5.7	15
91	Mechanisms of Action of the Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 12, 31-46	0.3	0
90	$\beta$ 2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. <i>Journal of Immunology</i> , <b>2017</b> , 198, 2640-2648	5.3	28
89	Antitumor activity of interferon- $\alpha$ 1a in hormone refractory prostate cancer with neuroendocrine differentiation. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 761-770	5.2	8
88	Synergistic activity of everolimus and 5-aza-2-Deoxycytidine in medullary thyroid carcinoma cell lines. <i>Molecular Oncology</i> , <b>2017</b> , 11, 1007-1022	7.9	18

87	Detection of early endothelial damage in patients with Raynaud's phenomenon. <i>Microvascular Research</i> , <b>2017</b> , 113, 22-28	3.7	16
86	Oxidation of $\beta$ -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186513	3.7	8
85	8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth. <i>Endocrine</i> , <b>2017</b> , 56, 388-398	4	1
84	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests <b>2017</b> , 171-187		2
83	The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines. <i>Endocrine</i> , <b>2016</b> , 51, 101-12	4	13
82	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 111	5.7	24
81	Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. <i>Acta Neuropathologica Communications</i> , <b>2016</b> , 4, 47	7.3	96
80	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 389-400	2.8	24
79	Antibodies and Diagnostic Tests in Antiphospholipid Syndrome <b>2016</b> , 495-501		
78	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , <b>2016</b> , 127, 365-7	2.2	51
77	Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1155-64	9.5	76
76	Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against $\beta$ -glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2196-204	9.5	68
75	Update on the pathogenesis and treatment of the antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , <b>2015</b> , 27, 476-82	5.3	29
74	Antiendothelial Cell Antibodies <b>2014</b> , 723-729		
73	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 609-15	2.4	97
72	Autoantibody profiling in APS. <i>Lupus</i> , <b>2014</b> , 23, 1262-4	2.6	12
71	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , <b>2014</b> , 10, 35-43	8.1	59
70	Immune parameters identify Italian centenarians with a longer five-year survival independent of their health and functional status. <i>Experimental Gerontology</i> , <b>2014</b> , 54, 14-20	4.5	25

69	β <sub>2</sub> -glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. <i>Journal of Autoimmunity</i> , <b>2014</b> , 55, 42-50	15.5	42
68	A non-complement-fixing antibody to β <sub>2</sub> glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , <b>2014</b> , 123, 3478-87	2.2	98
67	Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. <i>PLoS ONE</i> , <b>2014</b> , 9, e107743	3.7	24
66	Toll-like receptor 4 and β <sub>2</sub> glycoprotein I interaction on endothelial cells. <i>Lupus</i> , <b>2014</b> , 23, 1302-4	2.6	17
65	International standards for IgG and IgM anti-β <sub>2</sub> glycoprotein antibody measurement. <i>Lupus</i> , <b>2014</b> , 23, 1317-9	2.6	12
64	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. <i>Immunologic Research</i> , <b>2013</b> , 56, 432-8	4.3	43
63	A5.5 Antibodies against Domain I of β <sub>2</sub> Glycoprotein I in Antiphospholipid Antibody Syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A31.3-A32	2.4	
62	Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β <sub>2</sub> glycoprotein I phospholipid-binding site. Implications for human fetal loss. <i>Journal of Autoimmunity</i> , <b>2012</b> , 38, J209-15	15.5	47
61	Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. <i>Journal of Cellular and Molecular Medicine</i> , <b>2012</b> , 16, 1563-72	5.6	37
60	Interferon-inducible genes, TNF-related apoptosis-inducing ligand (TRAIL) and interferon inducible protein 27 (IFI27) are negatively regulated in leiomyomas: implications for a role of the interferon pathway in leiomyoma development. <i>Gynecological Endocrinology</i> , <b>2012</b> , 28, 216-9	2.4	8
59	Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R271	5.7	32
58	What is the Genetics of Antiphospholipid Antibodies/Syndrome? <b>2012</b> , 41-56		
57	Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1388-92	2.4	15
56	Obstetric and vascular APS: same autoantibodies but different diseases?. <i>Lupus</i> , <b>2012</b> , 21, 708-10	2.6	34
55	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity? <b>2012</b> , 79-101		0
54	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. <i>Nature Reviews Rheumatology</i> , <b>2011</b> , 7, 330-9	8.1	374
53	In vivo distribution of β <sub>2</sub> glycoprotein I under various pathophysiologic conditions. <i>Blood</i> , <b>2011</b> , 118, 4231-8	2.2	89
52	8-Chloro-cyclic AMP and protein kinase A I-selective cyclic AMP analogs inhibit cancer cell growth through different mechanisms. <i>PLoS ONE</i> , <b>2011</b> , 6, e20785	3.7	23

51	Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. <i>Lupus</i> , <b>2010</b> , 19, 453-6	2.6	37
50	Patients with antiphospholipid syndrome display endothelial perturbation. <i>Journal of Autoimmunity</i> , <b>2010</b> , 34, 105-10	15.5	59
49	IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1201-2		14
48	Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1504-12		43
47	European Forum on Antiphospholipid Antibodies: research in progress. <i>Lupus</i> , <b>2009</b> , 18, 924-9	2.6	3
46	Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 2468-71		52
45	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. <i>Journal of Autoimmunity</i> , <b>2009</b> , 32, 60-3	15.5	21
44	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2009</b> , 10, 55-67	0.3	3
43	Anti- $\beta$ -glycoprotein I ELISA assay: The influence of different antigen preparations. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 789-791	7	11
42	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. <i>Lupus</i> , <b>2008</b> , 17, 937-42	2.6	51
41	Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2008</b> , 34, 236-50	5.3	173
40	Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2008</b> , 34, 332-7	12.3	27
39	Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2007</b> , 32, 67-74	12.3	18
38	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 1327-33	2.4	160
37	Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. <i>Lupus</i> , <b>2007</b> , 16, 651-6	2.6	29
36	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES <b>2007</b> , 725-731		2
35	Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block: lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 356-9		23
34	Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1069, 364-76	6.5	19

33	Humoral autoimmunity against endothelium: theory or reality?. <i>Trends in Immunology</i> , <b>2005</b> , 26, 275-81	14.4	45
32	Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus. <i>Lupus</i> , <b>2004</b> , 13, 463-8	2.6	5
31	Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 85-92	4.5	46
30	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , <b>2004</b> , 3, 510-5	13.6	47
29	Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 1112-21	6.3	75
28	Endothelial cell activation by antiphospholipid antibodies. <i>Clinical Immunology</i> , <b>2004</b> , 112, 169-74	9	76
27	Inflammatory response and the endothelium. <i>Thrombosis Research</i> , <b>2004</b> , 114, 329-34	8.2	62
26	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. <i>Blood</i> , <b>2003</b> , 101, 3495-500	2.2	260
25	Endothelium activation in the anti-phospholipid syndrome. <i>Biomedicine and Pharmacotherapy</i> , <b>2003</b> , 57, 282-6	7.5	16
24	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 1602-13		118
23	Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2002</b> , 61, 608-11	2.4	54
22	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. <i>International Immunology</i> , <b>2001</b> , 13, 349-57	4.9	39
21	Interaction between chronically HIV-infected promonocytic cells and human umbilical vein endothelial cells: role of proinflammatory cytokines and chemokines in viral expression modulation. <i>Clinical and Experimental Immunology</i> , <b>2000</b> , 120, 93-100	6.2	20
20	Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. <i>European Journal of Pharmacology</i> , <b>1996</b> , 311, 213-20	5.3	5
19	Antiphospholipid and antiendothelial antibodies. <i>International Archives of Allergy and Immunology</i> , <b>1996</b> , 111, 320-5	3.7	2
18	In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. <i>Lupus</i> , <b>1996</b> , 5, 139-45	2.6	57
17	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. <i>Aids</i> , <b>1995</b> , 9, 691-4	3.5	26
16	Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin. <i>Scandinavian Journal of Immunology</i> , <b>1994</b> , 39, 333-6	3.4	9

15	Beta-endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. <i>Peptides</i> , <b>1994</b> , 15, 769-75	3.8	14
14	TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. <i>Aids</i> , <b>1994</b> , 8, 757-62	3.5	134
13	Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. <i>Clinical Immunology and Immunopathology</i> , <b>1992</b> , 63, 267-74		59
12	Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. <i>Clinical Immunology and Immunopathology</i> , <b>1992</b> , 65, 39-44		4
11	The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. <i>Scandinavian Journal of Immunology</i> , <b>1992</b> , 36, 415-20	3.4	16
10	In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. <i>Immunopharmacology</i> , <b>1992</b> , 24, 11-6		23
9	In vitro and ex vivo effect of tiaprofenic acid on human peripheral blood mononuclear cells. <i>International Journal of Immunopharmacology</i> , <b>1992</b> , 14, 1279-84		1
8	Immunopharmacological activity of cefodizime in young and elderly subjects: in vitro and ex vivo studies. <i>Infection</i> , <b>1992</b> , 20 Suppl 1, S61-3	5.8	7
7	FK-506 prevents diabetes in diabetes-prone BB/Wor rats. <i>International Journal of Immunopharmacology</i> , <b>1991</b> , 13, 1027-30		10
6	Immunopotentiating Activity of Thymopentin Treatment in Elderly Subjects <b>1990</b> , 537-550		
5	Heterogeneity of immune responsiveness in healthy elderly subjects. <i>Clinical Immunology and Immunopathology</i> , <b>1988</b> , 47, 142-51		52
4	In vivo immunopotentiating activity of thymopentin in aging humans: modulation of IL-2 receptor expression. <i>Clinical Immunology and Immunopathology</i> , <b>1988</b> , 48, 140-9		15
3	Experiences with immunomodulant agents in HIV infections. <i>Acta Haematologica</i> , <b>1987</b> , 78 Suppl 1, 84-90.	0.7	4
2	In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production. <i>Clinical Immunology and Immunopathology</i> , <b>1987</b> , 42, 151-9		42
1	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases		1